Boston Scientific (NYSE:BSX) said it’s beginning a limited U.S. launch of its Precision Spectra spinal cord stimulation device now that the FDA has approved it for treating chronic pain.
The Natick, Mass.-based medical device company said the device is designed to deliver controlled electrical pulses that mask pain signals on their way to the brain.
Boston Scientific won CE Mark approval in the European Union late last year for the device.
"The Precision Spectra system is a major milestone in the advancement of [spinal cord stimulation] therapy," Maulik Nanavaty, president of Boston’s neuromodulation business, said in prepared remarks. "The launch of the Precision Spectra system demonstrates our commitment to bringing meaningful innovations to market that provide more pain relief to a broader spectrum of patients."
